Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification.
|
29177434 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The correlations between anti-tumour sensitivity and the molecular segments of HER2, MET and FGFR2 alterations were further tested in a panel of GC cell lines and the patient-derived GC xenograft (PDGCX) model using the targeted inhibitors.
|
24518603 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion.
|
29263244 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the FGFR2 gene was identified in a subset of Chinese and Caucasian patients with gastric cancer.
|
23493349 |
2013 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Overall, 78% of GC cases harbored one clinically relevant GA or more, with the most frequent alterations being found in TP53 (50%), ARID1A (24%), KRAS (16%), CDH1 (15%), CDKN2A (14%), CCND1 (9.5%), ERBB2 (8.5%), PIK3CA (8.6%), MLL2 (6.9%), FGFR2 (6.0%), and MET (6.0%).
|
25882375 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR inhibitors may function against FGFR2-amplified GC, and a novel FGFR2-ACSL5 fusion identified by transcriptomic characterization may underlie clinically acquired resistance.
|
28122360 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
A similar incidence of FGFR2 amplification was found in Asian and UK GCs and was associated with lymphatic invasion and poor prognosis.
|
24457912 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer.
|
29786108 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
|
27230412 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer.
|
27245147 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Applying dual-colour FISH on 137 gastric tumours (89 FFPE surgical resections and 48 diagnostic biopsies), we observed FGFR2 amplification in 7.3% and HER2 amplification in 2.2% of GCs.
|
25086186 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplifications of certain RTKs (c-Met, FGFR2 and ErbB2) have been associated with human gastric cancer progression.
|
20331976 |
2010 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription.
|
27107424 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
It will be clinically valuable to investigate the involvement of RTK-mediated signaling in intrinsicor acquired resistance to FGFR2 TKIs in GC.
|
25576915 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments.
|
29876827 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using a three-dimensional organoid tissue model, we functionally validated the metastatic potential of an FGFR2 amplification in gastric cancer.
|
28629429 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Deep-sequencing of a primary tumor and metastasis from a single patient, and functional validation in culture, reveals that TGFBR2 and FGFR2 act as drivers of gastric cancer.
|
25222187 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers containing FGFR2 amplification.
|
18381441 |
2008 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, multivariate analysis indicated that FGFR2 amplification was not an independent prognostic factor for OS (HR=1.42, 95% CI: 0.77-2.61, p=0.261).Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy.
|
27802183 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
|
25972329 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance.
|
26254407 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer.
|
28852882 |
2018 |